Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ChemoCentryx, Inc. (CCXI)
|
Add to portfolio |
|
|
|
| Price: |
$47.18
| | Metrics |
| OS: |
71.2
|
M
| |
|
|
| Market cap: |
$3.36
|
B
| |
|
|
|
Net cash:
|
$372
|
M
| |
$5.22
|
per share
|
|
EV:
|
$2.99
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 32.2 | 64.9 | 36.1 | 42.9 | 82.5 | 11.9 | 0.0 | 0.0 |
| Revenue growth | -50.3% | 79.6% | -15.7% | -48.0% | 591.2% | | | -100.0% |
| Cost of goods sold | 162.1 | 120.1 | 94.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | -129.9 | -55.2 | -58.3 | 42.9 | 82.5 | 11.9 | 0.0 | 0.0 |
| Gross margin | -403.2% | -85.0% | -161.4% | 100.0% | 100.0% | 100.0% | | |
| Selling, general and administrative | 0.0 | 0.0 | 0.0 | | | | | |
| Research and development | | | | 62.7 | 49.5 | 37.9 | 33.2 | 33.8 |
| General and administrative | 0.0 | 0.0 | 0.0 | 20.4 | 16.5 | 14.7 | 14.5 | 13.6 |
| EBIT | -127.4 | -53.9 | -57.0 | -40.3 | 16.5 | -40.7 | -47.7 | -47.4 |
| EBIT margin | -395.4% | -83.0% | -157.7% | -93.9% | 20.0% | -341.2% | | |
| Pre-tax income | -131.8 | -55.4 | -55.5 | -38.0 | 17.9 | -40.0 | -47.3 | -46.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -131.8 | -55.4 | -55.5 | -38.0 | 17.9 | -40.0 | -47.3 | -46.9 |
| Net margin | -408.9% | -85.3% | -153.6% | -88.6% | 21.6% | -334.8% | | |
| |
| Diluted EPS | ($1.89) | ($0.84) | ($0.98) | ($0.76) | $0.36 | ($0.86) | ($1.08) | ($1.08) |
| Shares outstanding (diluted) | 69.9 | 65.7 | 56.9 | 49.8 | 49.6 | 46.4 | 43.9 | 43.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|